Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of heparan sulfate-based therapeutics to treat inflammatory diseases

Award Number: R43GM144019
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/14/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2023

Group Awards By:

View Award Description

Development of heparan sulfate-based therapeutics to treat inflammatory diseases - Abstract The goal of this SBIR phase I project is aimed at completing a larger synthesis scale and pharmacokinetic studies for 18-mer, a lead candidate anti-inflammatory heparan sulfate oligosaccharide. 18-mer decreased neutrophil infiltration in murine diseases model of peritonitis, liver ischemia/reperfusion injury, and acetaminophen-induced acute liver failure (APAP-induced ALF). 18-mer targets to high mobility group box 1 (HMGB1) protein and attenuates HMGB1- mediated inflammation characterized by neutrophil infiltration to the injury site. In addition to these disease models, HMGB1 is involved a numerous local and systemic inflammation disorders including sepsis and trauma injury. Currently, there are no approved therapeutics targeting HMGB1-mediated inflammation. This work is focused on developing 18-mer as a therapeutic for APAP-induced ALF. Confidence to pursue 18-mer stems from screening experiments using other oligosaccharides in the APAP model that were ineffective compared to 18-mer and demonstrating 18-mer’s anti-inflammatory effect is multiple inflammatory mouse models. This SBIR phase I application contains two specific aims. In Aim 1, we plan to increase the synthetic scale to 10 g, about 30-fold increase from the current production scale. The improved synthesis will use a 12-mer intermediate as the starting material, shortening the synthetic steps to 16 from 36. Aim 2 is to develop a LC- MS/MS based method to quantify the 18-mer in blood and urine. This method will allow us to obtain pharmacokinetic parameters in the subsequent preclinical development. In the phase II studies, we will focus on increasing the scale-up synthesis to 100g, IND-enabling studies and tissue distribution of the oligosaccharides. The success of this project will provide a new approach to treat drug induced liver toxicity by targeting to HMGB1-mediated inflammation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$180 )
2024	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	2/21/2024	NEW	-$180
														Subtotal = -$180

Issue Date FY: 2021 ( Subtotal = $231,139 )
2021	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	9/14/2021	NEW	$231,139
														Subtotal = $231,139

Grand Total All Awards = $230,959

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of heparan sulfate-based therapeutics to treat inflammatory diseases

Award Number: R43GM144019

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/14/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer